Will serputinib/serpatinib be included in medical insurance in 2024?

Selpercatinib/Selpercatinib (Selpercatinib) was approved for marketing by the National Medical Products Administration in 2022, but it has not yet been included in the medical insurance list, which means that patients currently need to purchase the drug at their own expense. As for whether seputinib will enter medical insurance in 2024, it depends on a variety of factors, including the drug's clinical efficacy, safety, price, and medical insurance policies. If seputinib can show better clinical data in the future and meet the requirements of the national medical insurance policy, it may enter the medical insurance.

In clinical trials, seputinib has shown significant effectiveness in treating cancers involving RET gene changes. These cancer types include RET fusion-positive non-small cell lung cancer, RET-altered medullary thyroid cancer, thyroid cancer, and other RET fusion-positive solid tumors. For many patients, seputinib can effectively reduce tumor size, bringing new hope to their treatment.

Up to now, the original drug is sold in China as Seputinib, and the price of each box of specifications80mg*56 capsules may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). There is also Seputinib overseasGeneric drugs are on the market, and their pharmaceutical ingredients are basically the same as those of original drugs sold domestically and abroad, such as the specifications produced by Laos Pharmaceutical FactoryThe price of each box of 40mg*120 tablets is more than 4,000 yuan (the price may fluctuate due to the exchange rate). For more overseas drug information and specific prices, please consult Yaode Medical Consultant.